Strongbridge Biopharma plc to Host Conference Call on August 7, 2017 to Provide KEVEYIS® Launch Update and Report Second Qua...
31 July 2017 - 9:00PM
Strongbridge Biopharma plc, (Nasdaq:SBBP), a global
commercial-stage biopharmaceutical company focused on the
development and commercialization of therapies for rare diseases
with significant unmet needs, today announced that it will host a
conference call with members of Strongbridge’s management team on
Monday, August 7 at 9:00 a.m. ET to provide a KEVEYIS® launch
update, discuss the Company’s second quarter 2017 financial results
and provide corporate highlights. The conference call will follow
the anticipated release of the Company’s financial results earlier
that day.
Event DetailsStrongbridge will
host a conference call on Monday, August 7 at 9:00 a.m. ET. To
access the live call, dial 844-285-7153 (domestic) or 478-219-0180
(international). The conference call will also be audio webcast
from the Company’s website at www.strongbridgebio.com under
the “Investor/Webcasts and Presentations” section. A replay of the
call will be made available for one week following the conference
call. To hear a replay of the call, dial 855-859-2056 (domestic) or
404-537-3406 (international) with conference ID 61074112.
About Strongbridge Biopharma
Strongbridge Biopharma is a global
commercial-stage biopharmaceutical company focused on the
development and commercialization of therapies for rare diseases
with significant unmet needs. Strongbridge's first commercial
product is KEVEYIS® (dichlorphenamide), the first and only
FDA-approved treatment for hyperkalemic, hypokalemic, and related
variants of Primary Periodic Paralysis. KEVEYIS has orphan drug
exclusivity status in the United States through August 7, 2022. In
addition to establishing this neuromuscular disease franchise, the
Company has a clinical-stage pipeline of therapies for rare
endocrine diseases. Strongbridge's lead compounds include
RECORLEV™ (levoketoconazole), a cortisol synthesis
inhibitor currently being studied for the treatment of endogenous
Cushing's syndrome, and veldoreotide, a next-generation
somatostatin analog being investigated for the treatment of
acromegaly, with potential additional applications in Cushing's
syndrome and neuroendocrine tumors. Both RECORLEV and veldoreotide
have received orphan designation from the U.S. Food and Drug
Administration and the European Medicines Agency. For more
information, visit www.strongbridgebio.com.
Contacts:
Corporate and Media Relations
Elixir Health Public Relations
Lindsay Rocco
+1 862-596-1304
lrocco@elixirhealthpr.com
Investor Relations
U.S.:
The Trout Group
Marcy Nanus
+1 646-378-2927
mnanus@troutgroup.com
Europe:
First House
Mitra Hagen Negård
+47 21 04 62 19
strongbridgebio@firsthouse.no
USA
900 Northbrook Drive
Suite 200
Trevose, PA 19053
Tel. +1 610-254-9200
Fax. +1 215-355-7389
Strongbridge Biopharma (NASDAQ:SBBP)
Historical Stock Chart
From Apr 2024 to May 2024
Strongbridge Biopharma (NASDAQ:SBBP)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Strongbridge Biopharma PLC (NASDAQ): 0 recent articles
More News Articles